June 2025 brought key clinical updates including FDA approvals of Gilead's twice-yearly HIV prevention shot and Nuvation Bio’s ROS1 inhibitor for lung cancer. Arvinas and Pfizer submitted their estrogen receptor PROTAC candidate for approval, while Monte Rosa Therapeutics plans phase 1 trials on NEK7 degraders for inflammatory diseases. Novo Nordisk is launching phase 3 trials with an amylin analog/GLP-1 agonist combo for weight loss. Diamedica’s DM-199 showed promising phase 2 results in preeclampsia, potentially improving maternal-fetal outcomes.